It's been standard practice for drug companies to pay doctors for promoting their products in speaking engagements and elsewhere, making some doctors rich but raising ethical questions. Now GlaxoSmithKline says it won't do that any more. But today's announcement from the sixth largest drug company -- maker of Advair, Lovaza and other products -- may be evolutionary, rather than revolutionary. That's according to Charles Ornstein, senior reporter at ProPublica and past president of the Association of Health Care Journalists.
KCRW
